Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ACAD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
June 30, 2026 100.78M
March 31, 2026 33.98M
December 31, 2025 -48.73M
September 30, 2025 74.29M
June 30, 2025 63.96M
March 31, 2025 20.32M
December 31, 2024 40.38M
September 30, 2024 63.25M
June 30, 2024 25.01M
March 31, 2024 29.08M
December 31, 2023 85.39M
September 30, 2023 -58.96M
June 30, 2023 8.201M
March 31, 2023 -17.93M
December 31, 2022 -23.85M
September 30, 2022 -0.727M
June 30, 2022 -13.12M
March 31, 2022 -76.33M
December 31, 2021 -23.12M
September 30, 2021 -17.06M
June 30, 2021 -25.33M
March 31, 2021 -60.15M
December 31, 2020 -27.49M
September 30, 2020 -22.79M
June 30, 2020 -36.88M
Date Value
March 31, 2020 -49.00M
December 31, 2019 -29.71M
September 30, 2019 -18.85M
June 30, 2019 -38.40M
March 31, 2019 -64.18M
December 31, 2018 -39.08M
September 30, 2018 -42.28M
June 30, 2018 -40.88M
March 31, 2018 -45.24M
December 31, 2017 -29.90M
September 30, 2017 -58.40M
June 30, 2017 -58.90M
March 31, 2017 -70.56M
December 31, 2016 -63.19M
September 30, 2016 -49.26M
June 30, 2016 -54.74M
March 31, 2016 -41.21M
December 31, 2015 -34.35M
September 30, 2015 -31.85M
June 30, 2015 -29.87M
March 31, 2015 -25.35M
December 31, 2014 -17.80M
September 30, 2014 -17.48M
June 30, 2014 -16.97M
March 31, 2014 -14.18M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Incyte Corp. 507.66M
Agios Pharmaceuticals, Inc. -57.31M
Biogen, Inc. 448.90M
Insmed, Inc. -88.83M
Vertex Pharmaceuticals, Inc. 1.125B